MP
PBAXU

Mangrove Partners’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Mangrove Partners’s Portfolio PBAXU Stock Details PBAXU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-199,900
Closed -$2.01M – 578
2022
Q1 		$2.01M Sell
199,900
-100
-0.1% -$1.01K 0.11% 272
2021
Q4 		$2.02M Buy
+200,000
New +$2.02M 0.12% 267

Other funds holding PBAXU

SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Mangrove Partners's PBAXU Position: Q2 2022 in Review

Mangrove Partners sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q2 2022, closing a stake of 199,900 shares — an estimated $2.01M sold.

Mangrove Partners first reported a position in PBAXU in Q4 2021 and held it in 2 quarters. The position peaked at $2.02M in Q4 2021. 26 funds tracked by Wall St. Rank hold PBAXU as of Q2 2022.

  • Mangrove Partners reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q2 2022 after selling out during the quarter.
  • Mangrove Partners sold 199,900 Phoenix Biotech Acquisition Corp. Unit shares in Q2 2022, an estimated $2.01M.
  • Mangrove Partners first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 2 quarters.
  • Mangrove Partners's Phoenix Biotech Acquisition Corp. Unit position peaked at $2.02M in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q2 2022.

Based on Mangrove Partners's 13F filing for Q2 2022, filed 15 Aug 2022.